• Compelling technology: Simple, ultra-rapid breath test to save lives, time and money
  • Thermometer for the lungs: Measuring bacterial load to enable better diagnoses, monitor therapy and mitigate the overuse of broad-spectrum antibiotics
  • $3.3 billion U.S. market opportunity for post-COVID-19 bronchiectasis and VAP alone, plus opportunity in multiple additional respiratory diseases and outside the U.S.
  • Clinical risk mitigated: Novel use of existing technology with clinical proof-of-concept
  • Sufficient funding to reach key value inflection points through product launch
  • Smart business model enables accelerated market entry

Subscribe to receive our press releases

Stock Info:
CSE:   AVBT $0.00